http://www.onconova.com/exrad.shtml
"Ex-RAD® (ON 01210.Na) is in Phase I clinical testing as a radiation protection agent. Radioactive contamination and injury from ionizing radiation can arise from accidents involving nuclear reactors and industrial or medical sources. Recent events have highlighted the potential for non-accidental radiation injury as a result of malicious, criminal, or terrorist actions. Pharmaceutical agents that can "prevent and repair" cellular radiation damage can help in mitigating radiation injury. Using a cell biology-based screening approach, we identified Ex-RAD® that provided protection from lethal ionizing radiation. Ex-RAD® development, which is initially focused on military applications, is being supported by a funded collaboration with the U.S. Department of Defense (DoD). Ex RAD® is being developed according to the FDA's Animal Rule - Marketing approval for new countermeasures for which human efficacy studies are not feasible or ethical would be based on animal studies and Phase I safety data in healthy volunteers, without Phase II or Phase III clinical studies." <more> Should it be offered to Fukushima workers? T
